BioSenic Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 7

Employees

  • Stock Symbol
  • BIOS

Stock Symbol

  • Investments
  • 1

BioSenic General Information

Description

Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Contact Information

Formerly Known As
Medsenic
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Avenue Leon Champagne, 3
  • 1480 Saintes
  • Belgium
+32 02
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
BRU
Vertical(s)
Corporate Office
  • Avenue Leon Champagne, 3
  • 1480 Saintes
  • Belgium
+32 02

BioSenic Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioSenic Stock Performance

As of 26-May-2026, BioSenic’s current market cap is $1.52M.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.52M 1.27M

BioSenic Financials Summary

As of 31-Dec-2025, BioSenic has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 31-Dec-2025 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 31,833 31,833 29,052 37,466
Revenue 0 0
EBITDA (1,493) (1,493) (5,299) (29,566)
Net Income (5,159) (31,140)
Total Assets 3,993 3,993 4,934 10,567
Total Debt 0 0 28,850 31,129
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioSenic Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioSenic‘s full profile, request access.

Request a free trial

BioSenic Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore BioSenic‘s full profile, request access.

Request a free trial

BioSenic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline
Drug Discovery
Saintes, Belgium
7 As of 2024

Woburn, MA
 

Liege, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioSenic Competitors (3)

One of BioSenic’s 3 competitors is Aurimi Therapeutics, a Venture Capital-Backed company based in Woburn, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aurimi Therapeutics Venture Capital-Backed Woburn, MA
ImCyse Formerly VC-backed Liege, Belgium
Equaly Venture Capital-Backed Louvain-la-Neuve, Belgium
You’re viewing 3 of 3 competitors. Get the full list »

BioSenic Patents

BioSenic Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4455672-A1 Method and kit for diagnosing and monitoring chronic graft-versus-host disease (cgvhd) using particular cytokine biomarkers Pending 26-Apr-2023
WO-2024223904-A1 Method and kit for establishing and monitoring treatments of chronic graft-versus-host disease (cgvhd) using cytokine or chemokines biomarkers Inactive 26-Apr-2023
EP-3988093-A1 Use of an arsenic compound for treating a cytokine storm Inactive 22-Oct-2020
EP-4527462-A2 Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune / inflammatory diseases in humans or animals Pending 03-Apr-2020
AU-2021247142-A1 Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animals Inactive 03-Apr-2020 A61P11/00
To view BioSenic’s complete patent history, request access »

BioSenic Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioSenic Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioSenic‘s full profile, request access.

Request a free trial

BioSenic Acquisitions (1)

BioSenic’s most recent deal was a Merger/Acquisition with Bone Therapeutics. The deal was made on 25-Oct-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Bone Therapeutics 25-Oct-2022 Merger/Acquisition Biotechnology
To view BioSenic’s complete acquisitions history, request access »

BioSenic ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view BioSenic’s complete esg history, request access »

BioSenic FAQs

  • When was BioSenic founded?

    BioSenic was founded in 2006.

  • Where is BioSenic headquartered?

    BioSenic is headquartered in Saintes, Belgium.

  • What is the size of BioSenic?

    BioSenic has 7 total employees.

  • What industry is BioSenic in?

    BioSenic’s primary industry is Drug Discovery.

  • Is BioSenic a private or public company?

    BioSenic is a Public company.

  • What is BioSenic’s stock symbol?

    The ticker symbol for BioSenic is BIOS.

  • What is the current market cap of BioSenic?

    The current market capitalization of BioSenic is $1.52M.

  • Who are BioSenic’s competitors?

    Aurimi Therapeutics, ImCyse, and Equaly are competitors of BioSenic.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process